PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 100 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2014. The put-call ratio across all filers is 0.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $4,423,000 | -46.4% | 716,880 | -54.9% | 0.26% | -16.2% |
| Q3 2014 | $8,249,000 | +20.4% | 1,589,363 | 0.0% | 0.31% | +22.6% |
| Q2 2014 | $6,850,000 | +21.0% | 1,589,363 | +14.9% | 0.25% | +11.5% |
| Q1 2014 | $5,659,000 | -27.6% | 1,383,729 | -5.6% | 0.23% | -47.1% |
| Q4 2013 | $7,816,000 | -28.8% | 1,466,382 | -32.9% | 0.43% | -39.9% |
| Q3 2013 | $10,978,000 | +12.6% | 2,186,853 | 0.0% | 0.71% | -5.2% |
| Q2 2013 | $9,753,000 | – | 2,186,853 | – | 0.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |